October 2024
·
3 Reads
Russian Journal of Bioorganic Chemistry
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
October 2024
·
3 Reads
Russian Journal of Bioorganic Chemistry
January 2024
·
60 Reads
·
1 Citation
Naunyn-Schmiedeberg's Archives of Pharmacology
Rosavin, a phenylpropanoid glycoside, is the specific index component and one of the main active components of Rhodiola rosea. Currently, there are few studies describing the antiaging effect of rosavin, and most of them are mainly based on in vitro antioxidant research. Our study aimed to investigate the antiaging activities and mechanisms of rosavin in Caenorhabditis elegans. Using Caenorhabditis elegans as the model, the lifespan of Caenorhabditis elegans under various stressors (heat and juglone) and normal conditions was studied, and the antioxidant activities of rosavin were discussed. To discover the underlying mechanisms, we analyzed daf-16 nuclear localization, the expression of the sod-3p::GFP fusion protein, mRNA levels, and loss-of-function mutants of IIS-associated genes. The results showed that rosavin significantly improved the lifespan of Caenorhabditis elegans under stress and normal conditions. Rosavin can increase the expression and activity of antioxidant enzymes and suppress the generation of malondialdehyde and ROS in nematodes. Additionally, it promotes the nuclear localization of daf-16 and improves the expression of the sod-3 gene in Caenorhabditis elegans. The data revealed that rosavin activated the insulin/IGF-1 signaling pathway by downregulating the upstream components daf-2 and age-1. In summary, these results verify that rosavin could increase the lifespan of Caenorhabditis elegans through the insulin/IGF-1 signaling pathway.
May 2023
·
211 Reads
·
17 Citations
Rat sarcoma (RAS), as a frequently mutated oncogene, has been studied as an attractive target for treating RAS-driven cancers for over four decades. However, it is until the recent success of kirsten-RAS (KRAS)G12C inhibitor that RAS gets rid of the title "undruggable". It is worth noting that the therapeutic effect of KRASG12C inhibitors on different RAS allelic mutations or even different cancers with KRASG12C varies significantly. Thus, deep understanding of the characteristics of each allelic RAS mutation will be a prerequisite for developing new RAS inhibitors. In this review, the structural and biochemical features of different RAS mutations are summarized and compared. Besides, the pathological characteristics and treatment responses of different cancers carrying RAS mutations are listed based on clinical reports. In addition, the development of RAS inhibitors, either direct or indirect, that target the downstream components in RAS pathway is summarized as well. Hopefully, this review will broaden our knowledge on RAS-targeting strategies and trigger more intensive studies on exploiting new RAS allele-specific inhibitors.
February 2023
·
16 Reads
·
3 Citations
Journal of Traditional Chinese Medical Sciences
Objective: To explore the anti-aging effects of chlorogenic acid (CGA) and the underlying mechanisms based on a Caenorhabditis elegans (C. elegans) model. Methods: The anti-aging activity of CGA was studied based on the body length, exercise behavior, lipofuscin content, antioxidative stress ability, swallowing frequency, body-bending frequency, and head-swinging ability of C. elegans. Through DAF-16 nuclear translocation and SOD-3-GFP fluorescence experiments, the effects of CGA on ROS levels, antioxidant enzyme activities, MDA content, mutant-strain lifespan, and anti-aging molecular signaling pathways were explored, as well as the underlying mechanisms. Results: CGA improved multiple indices of the nematode: body length was increased (all P
January 2022
·
9 Reads
SSRN Electronic Journal
... Given the prevalence of RAS mutations and their impact on distant metastasis and mortality, developing effective targeted therapies against RAS or its downstream effectors could significantly improve outcomes for a substantial proportion of thyroid cancer patients [37]. While RAS itself has historically been considered "undruggable," recent advances in targeted therapies, including those targeting downstream effectors of RAS, offer promising avenues for exploration in thyroid cancer [38]. ...
May 2023
... CGA can serve as a potential chemical chaperone and drug candidate for treatment of aggregation disorders. Recently the anti-aging potential of CGA has been observed [75]. Interaction Analysis of BSA, cyt c, and CGA Using Molecular Docking ...
February 2023
Journal of Traditional Chinese Medical Sciences